<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03920787</url>
  </required_header>
  <id_info>
    <org_study_id>2017/ST/222</org_study_id>
    <nct_id>NCT03920787</nct_id>
  </id_info>
  <brief_title>Evaluating the Effect of Inositol Supplementation in Overweight Children on Basal Insulin and Body Weight</brief_title>
  <official_title>Effects of Inositol Supplementation in Children With Excessive Body Weight and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alice Andreassi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lo.Li.Pharma s.r.l</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera San Paolo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera San Paolo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inositol in involved in the insulin pathway. In literature it has been demonstrated to
      improve insulin sensitivity and ovarian function in women affected by PCOS.

      In a preliminary study conducted on obese children between 7 and 15 years, the investigators
      have demonstrated that Inositol administration (Myo-inositol 1100 mg + D-Chiro-inositol 27,6
      mg + Folic Acid 400 μg) before a Glucose Oral Tolerance Test reduces the increase of insulin
      levels, particularly in subjects with basal insulin ≥ 15 uU/ml.

      So the aim of this study is to evaluate the potential therapeutic effect of inositol, as
      non-pharmacologic agent, in preventing tipe II diabetes in children.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Basal Insulin</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluation of the efficacy of inositol in reducing basal insulin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluation of the efficacy of inositol in reducing body weight</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Inositol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Inofolic Combi (Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg - Lo.Li Pharma S.r.l.) 2 capsules every day for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of placebo. 2 capsules every day for 1 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inofolic Combi</intervention_name>
    <description>Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg. 2 capsules every day for 1 month.</description>
    <arm_group_label>Inositol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules every day for 1 month</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  8-18 years old

          -  overweight or obesity

          -  basal insulin ≥ 20 uU/ml

        Exclusion Criteria:

          -  pubertal delay

          -  hypogonadism

          -  hypothyroidism or hyperthyroidism

          -  obesity-related genetic diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Mancini</last_name>
    <role>Study Director</role>
    <affiliation>AO San Paolo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mario Mancini</last_name>
    <phone>00393331009479</phone>
    <email>mancinis178@msn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alice Andreassi</last_name>
    <phone>00393401799869</phone>
    <email>aliceandreassi2@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AO San Paolo</name>
      <address>
        <city>Milan</city>
        <state>Mi</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Mancini</last_name>
      <phone>00393331009479</phone>
      <email>mancinis178@msn.com</email>
    </contact>
    <contact_backup>
      <last_name>Alice Andreassi</last_name>
      <phone>00393401799860</phone>
      <email>aliceandreassi2@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Mancini M, Andreassi A, Salvioni M, Pelliccione F, Mantellassi G, Banderali G. Myoinositol and D-Chiro Inositol in Improving Insulin Resistance in Obese Male Children: Preliminary Data. Int J Endocrinol. 2016;2016:8720342. Epub 2016 Nov 1.</citation>
    <PMID>27882052</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera San Paolo</investigator_affiliation>
    <investigator_full_name>Alice Andreassi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>inositol</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>overweight</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

